Page 4 - Sanket Koul

West Asia war: Pressure builds on developers to hike prices as costs rise

Rising construction costs raising margin pressures; timelines maybe pushed by 3-6 months; mid-to-small scale developers more impacted

US pharma tariffs: CDMOs with innovator exposure likely to take a hit

Branded, patented pharma companies that have not agreed to lower drug prices via MFN agreements will face 100 per cent tariffs

Firms with cancelled drug licences may face heat as Centre tightens rules

DCC discusses stricter norms to bar firms with cancelled licences from reapplying and proposes public disclosure of inspection findings to strengthen pharma regulation

Accenture leases 1.65 lakh sq ft office space in Noida for ₹195 crore

IT major signs five-year lease with Onward Coworkx in Noida, reflecting sustained demand for office space amid strong leasing activity in metro cities

Emcure slashes obesity drug Poviztra price by up to 55% amid competition

Emcure cuts Poviztra prices by up to 55% following Novo Nordisk's move, lowering monthly treatment costs for semaglutide-based obesity therapy in India

Medtech, pharma welcome duty relief, seek GST cuts on key inputs

Industry welcomes customs duty exemption on petrochemicals but urges GST relief on inputs and faster refunds to ease cost pressures amid West Asia disruptions

Mahagun Group secures ₹225 crore from CSL Finance to speed up delivery

Mahagun Group raises Rs 225 crore from CSL Finance to accelerate construction and improve liquidity, following its recent exit of Blackstone-backed ASK Property Fund

Indian drugmakers may lose up to $750 million if Iran war drags on

Indian pharmaceutical companies may face losses of up to $750 million if the West Asia conflict continues, amid supply chain disruptions and rising logistics costs

M3M to deploy ₹14,500 crore to fund construction of 45 mn sqft portfolio

M3M India plans to deploy ₹14,500 crore to accelerate construction of over 45 million sq ft, funded through internal accruals and working capital

As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices

Drugmaker says it will not undertake similar steps for its oral semaglutide brand Rybelsus

Signature Global, RMZ complete ₹1,293 cr deal to fund Gurugram project

RMZ acquires 50 per cent stake in subsidiary GCL; partners form joint venture to develop large mixed-use commercial project on Gurugram's Southern Peripheral Road corridor

Corona Remedies acquires Wokadine from DRL, enters iodine market

Acquisition of Wokadine marks Corona Remedies' entry into India's Rs 648 crore povidone iodine segment, strengthening its specialty portfolio and distribution reach

CDSCO asks states to maintain vigil on unlicensed IVF device sales

Regulator flags rise in unlicensed IVF device sales as smaller fertility centres turn to cheaper alternatives amid pricing pressures and lack of awareness

Golden Growth Fund aims to liquidate two projects, buy land in FY27

Real estate AIF plans to exit two independent floor projects and acquire land parcels in South and Lutyens' Delhi, amid rising luxury housing demand and price appreciation

Dubai on the edge: Indian HNIs don't loosen grip on trophy assets

Luxury real estate mkt holds firm; investors selective about buying

Table Space leases 1.45 lakh sq feet commercial space in Gurugram

According to transaction documents accessed by Propstack, the company will pay rent for a chargeable area of 145,181 square feet, putting the monthly rent rate at ₹185 per square foot

Taxiing to take off, Jewar airport likely to drive land value surge

Infrastructure push, industrial growth and relative affordability are expected to drive residential demand and investor interest across Jewar, Noida and Greater Noida markets

Office leasing up 15% on-year in Jan to Mar 2026 on occupier demand

Office leasing in India's top cities rose 15% in Q1 CY26, driven by strong occupier demand and GCC expansion, with flex leasing also gaining a larger share

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

Drug pricing regulator permits marginal MRP increase for NLEM medicines in line with wholesale price index, offering relief to manufacturers facing higher costs

Govt to intensify surveillance, audits against unauthorised GLP-1 sales

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations